Cell & Tissue Therapies WA
Cell & Tissue Therapies Western Australia (CTTWA) at Royal Perth Hospital (RPH) provides manufacturing services to clinical specialities at RPH and WA Health, manufacturing a range of biological medicines that are based on genes, cells or tissues - Advanced Therapy Medicinal Products (ATMPs).
For over a decade, CTTWA’s state-of-the-art certified cleanroom suites have enabled the innovation and translation of emerging biotherapies, achieving remarkable clinical outcomes with cell therapies and tissue regeneration. CTTWA can translate research into clinical practice and promptly provide new treatments to patients as they emerge.
Research interests and focus
CTTWA collaborates with diverse clinical, commercial, and basic science research groups nationally and internationally to enable research translation into innovative therapies. Core services and capabilities include:
- Foundation for Accreditation of Cellular Therapy (FACT) accreditation for minimal and more than minimal manipulation cellular therapy processing
- Therapeutic Goods Administration (TGA) licensed manufacture of allogeneic and autologous serum eyedrops
- TGA Licensed manufacture of Mesenchymal Stromal Cells for clinical trials, including tissue regeneration and regenerative medicine
- Place-of-care manufacturing of ATMPs
- Receipt, storage, formulation, and administration of approved and investigational ATMPs
- GMP-compliant process development to facilitate research translation to clinical practice
- Contract manufacturing of ATMPs
Example Projects
Manufacture of autologous Tumour Infiltrating Lymphocytes (TIL) for the treatment of Melanoma
Dr Peter Lau (Harry Perkins Research Institute); A/Prof Zlatibor Velickovic (EMHS)
Manufacture of corneal endothelial cells for injection to treat corneal oedema and visual impairment leading to blindness
CPI Dr Evan Wong (Lions Eye Institute); A/Prof Zlatibor Velickovic (EMHS)
Bone constructs with cell-scaffold complexes for cranial reconstruction
CPI Dr Stephen Honeybul (EMHS)